Russell Investments Group
PRLD icon

Russell Investments Group’s Prelude Therapeutics PRLD Stock Holding History

Russell Investments Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8K Buy
+2,220
New +$9.66K ﹤0.01% 3901
2024
Q4 		– Sell
-76
Closed -$157 – 3771
2024
Q3 		$157 Sell
76
-1,405
-95% -$6.51K ﹤0.01% 3656
2024
Q2 		$5.64K Buy
+1,481
New +$6.03K ﹤0.01% 3188

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Russell Investments Group's PRLD Position: Q2 2026 in Review

Russell Investments Group opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 2,220 shares worth $11.8K. The stake represents ﹤0.01% of the portfolio and ranks #3901 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in PRLD as recently as Q3 2024.

Russell Investments Group first reported a position in PRLD in Q2 2024 and has held it in 3 quarters since. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Russell Investments Group held 2,220 shares of Prelude Therapeutics worth $11.8K as of Q2 2026.
  • Prelude Therapeutics was a new Russell Investments Group position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3901 holding.
  • Russell Investments Group first reported a position in Prelude Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.